MI-UPSTREAM-SECURITY
10.4.2024 16:07:32 CEST | Business Wire | Press release
Upstream Security, a leading provider of cybersecurity extended detection and response (XDR) for connected vehicles and IoT, today announced it received an investment from Cisco Investments. The proliferation of complex IoT devices in the Mobility, Automotive, and Transportation sectors introduces unprecedented operational efficiencies, data-driven services and solutions, and exceptional customer experience. However, advanced connectivity and software-defined components also open the door for large-scale cyber risks, threatening business availability and data integrity.
Upstream already protects millions of mobility connected vehicles and IoT devices worldwide, offering a cloud-based multi-layered approach to extended detection and response.
“We are thrilled to welcome Cisco Investments to our group of investors,” states Yoav Levy, Upstream Security Co-founder and CEO. “This investment provides a unique opportunity to deepen our impact on the IoT sector, and more specifically Mobility, Automotive and Transportation.”
This investment by Cisco Investments amplifies the need for purpose-built IoT cybersecurity solutions that will safeguard the mobility and IoT ecosystem across the entire development and production lifecycle.
“Together with our partners, Cisco is enabling automobile manufacturers across the globe to provide mission-critical, secure connectivity as cars transform into data centers on wheels," says Cisco Investments vice president, Aleem Rizvon. “With an expected 95% of new vehicles having embedded connectivity by the year 2030, we can also expect a rise in automotive cybersecurity threats. Investing in solutions, to ensure the right safeguards for secure connectivity and operation are in place, is critical to instill the trust needed for wide adoption of the technology, not just in the automotive segment, but more broadly for other IoT applications, as well.
Disrupting the IoT Cybersecurity Landscape
Upstream’s cloud-based IoT XDR platform analyzes, in real-time, the contextual state of physical IoT assets and their connected ecosystem, to holistically identify and mitigate cyber risks. The Platform is agentless, requiring no installation of software or hardware, enabling rapid deployment and comprehensive coverage of devices already in production.
The Platform ingests, parses, and normalizes vast amounts of connected vehicle data, IoT protocols, telematics, API transactions, and other data streams from tens of millions of devices, endpoints, and application consumers. This data enables the creation of unique digital twins—near real-time representations of devices and endpoints, facilitating holistic and effective detection. By monitoring devices, services, and overall asset behavior, the Platform detects both known and unknown anomalies based on proprietary ML-powered models.
Coupled with a purpose-built vehicle security operation center (vSOC), dedicated for monitoring and investigating connected vehicles and IoT cyber threats, Upstream provides a holistic suite of cybersecurity solutions and services to enable customers to proactively identify and remediate cyber threats. Utilizing Upstream’s Ocean AI, Generative AI-powered capabilities, accelerates the investigation remediation process.
About Upstream Security
Upstream provides a cloud-based data management platform purpose-built for mobility and IoT, delivering unparalleled cybersecurity extended detection and response (XDR) and data-driven applications. The Upstream Platform secures more than 25 million connected vehicles and IoT devices and is trusted by large vehicle manufacturers and IoT service providers.
Upstream recently published its 2024 Automotive Cybersecurity Report, providing a detailed analysis of the cyber landscape across the Automotive and Mobility ecosystem, emerging risks, and the evolving regulatory landscape.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240410994590/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
FDA Issues Modified Risk Tobacco Product Orders for 20 ZYN Nicotine Pouch Products30.6.2026 18:19:00 CEST | Press release
FDA’s decision makes ZYN the first nicotine pouch product to receive MRTP orders authorizing reduced-risk claims versus cigarettes Philip Morris International Inc. (PMI) (NYSE: PM) today announced that the U.S. Food and Drug Administration (FDA) issued Modified Risk Tobacco Product (MRTP) orders for 20 variants of ZYN nicotine pouch products. These are the first MRTP orders granted for nicotine pouches, allowing PMI U.S. to market the following claim for the authorized ZYN products: “Using ZYN instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.” “FDA’s decision is an important moment for the more than 45 million legal-age nicotine consumers in America,” saidStacey Kennedy, PMI U.S. CEO. “Today’s news ensures these adultshave access to accurate, science-based information, including FDA-authorized evidence that switching from cigarettes to ZYN reduces the risk of smoking-related diseases like heart disease
Caidya Announces Strategic Combination with Simbec-Orion Bridging Early Scientific Insight and Global Clinical Execution30.6.2026 17:00:00 CEST | Press release
Caidya today announced a strategic combination with Simbec-Orion designed to close the divide between early scientific insight and global clinical execution. The combination of Caidya and Simbec-Orion creates a differentiated specialty clinical CRO platform that enables programs to scale, maintaining focus, speed, and accountability. The strategic combination brings together complementary strengths to create a more complete development partner for innovative biopharma companies. With established operations across Europe, the Americas, APAC, and China, the combined organization provides meaningful expertise and execution capabilities in the regions that matter most. Simbec-Orion brings early-phase clinical pharmacology capabilities alongside deep therapeutic expertise for later stage complex oncology and rare disease trials, helping sponsors shape critical decisions early in the development lifecycle. Together, the organizations strengthen their ability to support complex, cross-border
Archer® Proves Purpose-Built AI Beats General-Purpose LLMs on Regulatory Change Management: 95% Verified Accuracy, 80x Faster, 92% Lower Cost30.6.2026 16:13:00 CEST | Press release
In a head-to-head benchmark, a leading general-purpose LLM was confidently wrong 35% of the time on regulatory dates. Archer Evolv™ shipped zero errors. For enterprises deploying AI in compliance, a wrong date is a missed deadline. The more dangerous failure is a wrong answer the model returns with high confidence, one that flows silently into a compliance calendar and is only discovered after the window has passed. Archer® today released results showing purpose-built AI beats a general-purpose large language model (LLM) on regulatory work, and it’s not close. This head-to-head test compared Archer’s purpose-built, vertical-specific AI and proprietary data sets against a leading general-purpose LLM, on a core compliance task: determining the publication, effective and comment-close dates of regulatory documents across six jurisdictions. General-purpose models are a genuine breakthrough, and this is no referendum on their quality. The question Archer set out to answer is narrower and mo
Altasciences Supports Key Development Milestone for Steel Therapeutics’ Lead Therapeutic Candidate, Fizurex™30.6.2026 16:08:00 CEST | Press release
Altasciences, a leading drug development organization, today announced a significant milestone in the development of Steel Therapeutics, Inc.’s pivotal toxicology study for its lead product candidate, Fizurex™, for the treatment of anal fissures. The successful completion of the study plays a significant role in the advancement of Fizurex™ toward first-in-human trials. The GLP-compliant study demonstrated a favorable safety profile, which has advanced Steel Therapeutics' plans to submit an Investigational New Drug (IND) application for Fizurex™ to the FDA in Q3 2026. Fizurex™, a patent-pending, single-use topical wipe, was designed to provide a standardized, accessible treatment option for a painful and often undertreated medical condition. The product builds on years of use through compounding pharmacy prescriptions and is now advancing toward clinical development and regulatory review. "We are proud to have supported Steel Therapeutics with the generation of the high-quality safety d
Interactive Brokers Expands Access to Korean Equities with Launch of Nextrade ATS30.6.2026 16:00:00 CEST | Press release
IB SmartRouting℠ Routes Orders to the Best Available Price Between KRX and Nextrade Interactive Brokers (Nasdaq: IBKR), an automated global broker, today announced the launch of select Korean equities through Nextrade, South Korea's first Alternative Trading System (ATS). The addition of Nextrade builds on Interactive Brokers' earlier launch of the Korea Exchange (KRX), through which it became the first major US-based broker to provide global investors with direct access to Korean equities. Clients trading on Nextrade benefit from significantly extended trading hours and access to additional liquidity. Interactive Brokers has enabled IB SmartRouting℠ across both the Korea Exchange (KRX) and Nextrade, automatically routing orders to the venue offering the best price. This helps clients achieve best execution while providing greater flexibility and more opportunities to participate in one of Asia's most dynamic equity markets. Korea's equity market ranks among the top global exchanges by
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom